Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized first-line therapy for metastatic non-clear cell renal carcinoma
2019-001316-38Phase 2Active
- Sponsor
- Department of Oncology, Herlev University Hospital
- Start
- May 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib, erlotinib, pembrolizumab, trametinib, alectinib and 9 more in non-clear cell renal cell carcinoma (nccRCC), renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC), sponsored by Department of Oncology, Herlev University Hospital. Primary endpoint: Overall response rate. Started May 2019; status: active.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2019-001316-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001316-38.